[Clinical applications of TRAIL in cancers. The prostate cancer example].
Hesry
V
V
Guillaudeux
T
T
Patard
J J
JJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D051017:Apoptosis Regulatory Proteins; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D008562:Membrane Glycoproteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha